TITLE

Stalled US plan for Plan B

AUTHOR(S)
Shuchman, Miriam
PUB. DATE
December 2005
SOURCE
CMAJ: Canadian Medical Association Journal;12/6/2005, Vol. 173 Issue 12, p1437
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Focuses on the controversy over the proposal to make Barr Laboratories' abortion drug Levonorgestrel (Plan B) an over-the-counter drug in the U.S. Reason behind the resignation of U.S. Food and Drug Administration director of women's health Susan Wood; Arguments for and against the proposal; Decision of the U.S. Congress on the issue.
ACCESSION #
18939129

 

Related Articles

  • Waxman alleges Troy blocked Plan B decision. J. G. D. // Medical Marketing & Media;May2006, Vol. 41 Issue 5, p16 

    The article reports on U.S. Representative Henry A. Waxman's March 9, 2006 letter to the U.S. Food and Drug Administration (FDA) alleging that former chief counsel Dan Troy failed to complete a necessary legal review of Barr Laboratories' proposed under-16 sales restriction on over-the-counter...

  • Facing mounting pressure, FDA soon may decide whether to go to Plan B. Johnsen, Michael // Drug Store News;8/28/2006, Vol. 28 Issue 10, p5 

    The article reports on the pressure for the U.S. Department of Food and Drug Administration (FDA) to switch to the emergency contraceptive Plan B. The FDA is expected to decide whether to approve or deny the sale of the "morning after" pill over the counter to women over the age of 18. The...

  • FDA Women's Health Director Resigns in Protest. Wood, Susan // Medical Design Technology;Oct2005, Vol. 9 Issue 11, p8 

    The article reports that U.S. Food and Drug Administration health director Susan Wood has resigned in protest over the agency's handling of Barr Laboratories Inc.'s Plan B emergency contraceptive application. The agency announced on August 26, 2005, that it could not issue a decision on the...

  • SAFETY GRILL. Wechsler, Jill // Pharmaceutical Executive;Apr2005, Vol. 25 Issue 4, p24 

    Reports on the concerns aired by senators about the ability of the U.S. Food and Drug Administration (FDA) to regain public confidence in its monitoring of drug safety. Call of several committee members for a drug safety office independent of the agency's drug approval bureaucracy; Demand of...

  • More states address issue of Plan B without a prescription. Dickinson, James G. // Medical Marketing & Media;Aug2005, Vol. 40 Issue 8, p15 

    Reports that New York and New Hampshire have joined several other states in approving legislation to allow pharmacists to dispense Barr Laboratories' Plan B emergency contraceptive without a doctor's prescription. States permitting the product's availability without a prescription; U.S. Food and...

  • FDA official resigns over emergency contraception decision. Tanne, Janice Hopkins // BMJ: British Medical Journal (International Edition);9/10/2005, Vol. 331 Issue 7516, p532 

    Reports that the assistant commissioner for women's health at the U.S. Food and Drug Administration, Susan Wood, has resigned. Coincidence of the resignation with the agency's announcement that it plans to postpone a decision on over the counter emergency contraception for teenagers; Inability...

  • Legal issues, not politics, delaying Plan B: Downey. J. G. D. // Medical Marketing & Media;Jun2005, Vol. 40 Issue 6, p18 

    This article presents views of Barr Laboratories Inc.'s chief executive Bruce Downey, that legal issues are delaying the decision of the U.S. Food and Drug Administration on making Plan B, the first dual Rx OTC drug. Downey said he understood from reading published reports that the scientific...

  • OTC ingredient listing can wait for rule.  // Medical Marketing & Media;Apr98, Vol. 33 Issue 4, p34 

    Announces that OTC drug manufacturers will be allowed to postpone complying with Modernization ACT provisions of the United States (U.S.) Food and Drug Administration (FDA). What the provisions require; Reference to a guidance interpretation which was issued.

  • OTC Labels Get a New Look.  // Pharmaceutical Executive;Sep2002, Vol. 22 Issue 9, p26 

    Reports on the U.S. Food and Drug Administration and the Consumer Healthcare Products Association's release of a consumer information brochure to promote awareness of new over-the-counter (OTC) product labels. Efforts to help consumers comprehend the importance of reading and following OTC...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics